Eyebright

What Eyebright does

Eyebright Medical Technology (Beijing) Co., Ltd. (爱博诺德) is a publicly listed Chinese ophthalmic medical device manufacturer headquartered in Beijing's Zhongguancun Changping Park and listed on the Shanghai Stock Exchange STAR Market (stock code 688050) in 2020. Founded in 2010 by Dr. Xie Jiangbing, the company operates across three product segments covering the full eye health lifecycle: ophthalmic surgical treatment (intraocular lenses including monofocal, multifocal, extended depth of focus, and phakic IOLs, plus surgical instruments and a 4K3D surgical imaging system), myopia prevention and control (orthokeratology lenses, peripheral defocus spectacle lenses, myopia control soft contact lenses, and RGP lenses), and consumer vision care (contact lenses, optical spectacle lenses, and care solutions). The portfolio is built on proprietary technology platforms including aspheric optical design, aberration-control EDoF optics, B.C.M.D. bionic compound-eye defocus, GradientHA® hyaluronic acid gradient release, EDF depth-of-focus extension, Balacrylic™ material, and an AI-powered orthokeratology fitting system, with seven years of accumulated international clinical data covering 859+ cases across Germany, France, Italy, Bulgaria, and Australia.

Name

Eyebright

Legal name

爱博诺德（北京）医疗科技股份有限公司

Website

https://ebmedical.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Eyebright Medical is a STAR Market-listed Chinese ophthalmic medical device manufacturer serving the full eye health lifecycle through surgical IOLs, myopia control lenses, and consumer vision care products across China, Europe, and emerging markets.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Surgical and Medical Instrument Manufacturing (339112)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)

Keywords

• Ophthalmic medical devices
• Intraocular lenses
• Orthokeratology lenses
• Myopia control products
• Contact lenses

Headquarters

HQ city

Changping

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Surgical Treatment Products: Revenue from intraocular lenses (普诺明® series, 普诺特® series, 龙晶® series), surgical instruments (利尔美® series), and related surgical products. Includes high-value Class III implantable medical devices sold to ophthalmic hospitals and eye centers. Also includes 4K3D surgical imaging systems and hand-held meibomian gland thermal pulsation devices.
2. Myopia Prevention and Control Products: Revenue from orthokeratology lenses (角膜塑形镜), peripheral defocus spectacle lenses (离焦框架镜 including 普诺瞳® series), myopia control soft contact lenses, RGP lenses, and associated care products (护理液, lubricant, enzyme cleaner). Sold to eye hospitals, optometry chains, and consumers.
3. Vision Care Consumer Products: Revenue from contact lenses (奥克拉® series, 澜柏® series, 缤瞳® series), optical lenses (optical lens series), and care products (诺清® series). Sold through retail channels, optical stores, and direct-to-consumer.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Eyebright Medical manufactures and sells ophthalmic medical devices across three integrated segments: (1) surgical treatment - intraocular lenses (monofocal, multifocal, EDoF), phakic IOLs, surgical instruments and 4K3D surgical imaging systems; (2) myopia prevention and control - orthokeratology lenses (OK lenses), peripheral defocus spectacle lenses, and myopia control soft contact lenses with AI fitting; (3) vision care - transparent and colored contact lenses, optical lenses, and care solutions. Products are sold to hospitals, eye centers, optometry networks, and consumers in China and overseas markets.

Product overview

Eyebright (爱博诺德) is a STAR Market listed (688050) ophthalmic medical device manufacturer offering a comprehensive portfolio across three core segments: surgical treatment ( intraocular lenses and surgical instruments), myopia control (orthokeratology lenses, defocus glasses, and contact lenses), and vision care (contact lenses and optical lenses). The company provides integrated solutions for ophthalmic surgery, refractive error correction, and optical consumption, covering the entire eye health lifecycle. Core product brands include 普诺明® (IOLs), 龙晶®PR (phakic IOL), 普诺瞳® (orthokeratology and defocus lenses), 澜柏® and 奥克拉® (contact lenses), and 诠式® (optical lenses).

Differentiator

Problem solved

Functional benefit

Brands

• 普诺明® (Proming): Intraocular lens product series for cataract surgery
• 普诺瞳® (Pinoutong)
• 龙晶® (Longjing)
• 普诺特®
• 利尔美®
• 欣诺瞳®
• 荧美®
• 奥克拉® (Aokela)
• 澜柏® (Lanbai)
• 缤瞳®
• 丝特保®
• 全景®

Products and services

• 普诺明® 全景® EDoF焦深延长型人工晶状体 (Proming® Panorama® Extended Depth of Focus IOL) Extended Depth of Focus (EDoF) intraocular lens using proprietary aberration control technology with no diffractive rings and no optical boundary. Provides focus extension through spherical aberration control with distant vision comparable to monofocal lenses and 2.0D near focus depth (1.0D improvement over monofocal). Effectively avoids glare and halos. Indicated for cataract and refractive lens surgery in adults.
• 龙晶®PR型非球面有晶体眼人工晶状体 (Longjing® PR Phakic Posterior Chamber IOL) Posterior chamber phakic intraocular lens for myopia correction using proprietary Balacrylic™ material with zero spherical aberration aspheric optical design. Provides a reversible refractive surgery option for highly myopic patients who are not suitable candidates for corneal laser surgery (LASIK).
• 4K3D显微手术成像系统 (4K3D Surgical Microscope Imaging System) AMSE4K3D dual 4K-channel surgical microscope imaging system with high-speed data processing chip achieving 30ms ultra-low latency for real-time heads-up display surgery. Reduces retinal phototoxicity risk through lower illumination requirements and supports immersive surgical teaching.
• 手持式睑板腺热脉动治疗仪 (Handheld Meibomian Gland Thermal Pulsation Device DE200) DE200 model handheld device integrating warm compression and massage functions for treating meibomian gland dysfunction and dry eye disease in ophthalmic clinics.
• 丝特保®可吸收内固定系统 (Sitebao® Absorbable Internal Fixation System) China's first Class III absorbable orbital implant using stereocomplex PLA and hydroxyapatite composite material for orbital bone defect repair. Indicated for ophthalmic and craniofacial reconstruction surgery; absorbed safely by the body over time.
• B Plus 仿生复眼离焦镜 (B Plus Bionic Compound-eye Defocus Lens) Enhanced B-series spectacle lens for myopia control in children and adolescents. Features 1038 hexagonal micro-lenses with smaller central optical zone and extended defocus area for improved myopia control efficacy using bionic compound-eye multifocal defocus technology.
• 普诺瞳® AI数字验配OK镜系统 (Pinoutong® AI Digital Orthokeratology Lens Fitting System) AI-powered fitting algorithm processing corneal topography data to output full parameterized orthokeratology lens customization plans in 20 seconds. Achieves 360-degree parallel fitting to corneal shape with nanometer-level processing precision. Used by optometrists for OK lens prescription.
• 角膜塑形用硬性透气接触镜 (Orthokeratology Lens / OK Lens) Rigid gas permeable contact lens worn overnight to reshape the cornea for myopia correction and control in children and adolescents. Uses proprietary full-arc aspherical design to optimize peripheral defocus, improving lens centering and wearing comfort.
• 硅水凝胶日抛透明隐形眼镜 (Silicone Hydrogel Daily Disposable Contact Lens) Daily disposable silicone hydrogel contact lens using third-generation Si+H₂O dual-channel material structure. Provides 114 DK/t oxygen transmissibility (8x higher than conventional hydrogel) for daily wear comfort and ocular health.
• EDF+高次非球面半年抛透明隐形眼镜 (EDF+ High-order Aspheric Semi-annual Replacement Contact Lens) Semi-annual replacement contact lens using EDF (Extended Depth of Focus) aberration intervention and high-order aspheric design to deliver continuous clear vision across distance, intermediate, and near focal ranges for presbyopia correction.
• 普诺瞳® 高次非球面软性亲水接触镜 (Pinoutong® High-order Aspheric Soft Myopia Control Contact Lens) Daily disposable soft contact lens for myopia control in children and adolescents. Uses high-order aspheric progressive defocus design with 5.00D defocus power and 86 Dk/t oxygen permeability to slow myopia progression.
• 诠式®全弧高次非球面镜片-X型多焦 (Quanshi® Full-arc High-order Aspheric X-type Multifocal Spectacle Lens) Full-arc high-order aspheric multi-focal spectacle lens with smooth power transition from center to periphery. Delivers clear near, intermediate, and distance vision for presbyopia correction.

Quantifiable outcome

• Extended depth of focus IOL (全景®/zoe®): distant and intermediate uncorrected vision ≥0.8, near vision ≥0.6, distant and intermediate spectacle-free rate of 98% in 859 clinical cases domestically and internationally
• +4 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Six partnerships are on record, tiered core, major and minor.

• China Association for Medical Devices Industry (中国医疗器械行业协会)coreOthers · 1 January 2026Dr. Xie Jiangbing, Chairman and General Manager, was elected as Vice President of the 7th Council of the China Association for Medical Devices Industry. This leadership position provides strategic influence in industry policy development, standards setting, and cross-industry collaboration.
• Delta MedicalmajorStrategic or Co-development Partner · 1 January 2025Strategic acquisition of Delta Medical to enter the sports medicine market. This acquisition enabled Eyebright Medical to expand its product portfolio into sports medicine, diversifying beyond ophthalmic devices and creating new revenue streams.
• Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's HospitalcoreStrategic or Co-development Partner · 1 January 2025Collaborative development partner for 丝特保®可吸收内固定系统, led by Prof. Fan Xianqun as project leader under the national key R&D program. Prof. Fan Xianqun is a renowned orbital and oculoplastic surgeon.
• Swiss Trade and Investment Office (瑞士贸易与投资处)majorGTM or Marketing Partner · 1 January 2025Official invitation to participate in Swiss Biotech Week for the second time, as a representative Chinese enterprise. The Swiss office facilitates对接 with global top biotech companies and research institutions, and supports Eyebright's European market presence through Eyebright Switzerland.
• Hong Kong Science ParkminorGTM or Marketing Partner · 1 January 2025Featured in Hong Kong Science Park special exhibition zone at Hong Kong International Healthcare Expo. Selected as one of only two ophthalmic medical companies recommended by Hong Kong Science Park, supporting market development in the Greater Bay Area and Southeast Asia.
• Multiple Clinical Research InstitutionscoreStrategic or Co-development Partner · 1 January 2025Collaborates with top domestic clinical institutions including Zhejiang University affiliated Second Hospital (姚克教授), Beijing Tongren Hospital, Peking Union Medical College Hospital, and international clinical researchers in Germany, Italy, France, Bulgaria, Australia for clinical validation of IOL products.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Alcon: Global leader in ophthalmic medical devices with a direct overlap in IOLs (PanOptix, Vivity), surgical instruments, contact lenses, and contact lens care solutions — Alcon is Eyebright's primary global competitor across both its surgical and vision-care franchises.
• Bausch + Lomb: Competes head-to-head with Eyebright across IOLs, contact lenses (Biotrue, Ultra), and lens care solutions. Bausch + Lomb's diversified portfolio across surgical, vision care, and consumer eye health makes it one of the closest direct comparables to Eyebright's three-segment model.
• Johnson & Johnson Vision: Competes in premium IOLs (TECNIS Symfony EDoF, TECNIS Multifocal) and contact lenses (Acuvue). Directly comparable to Eyebright's 全景® EDoF IOL and silicone hydrogel daily disposable contact lens offerings.
• Carl Zeiss Meditec: Manufacturer of surgical microscopes (analogous to Eyebright's 4K3D surgical imaging system), IOLs (CT LUCIA, AT ELANA), and ophthalmic diagnostic equipment — a direct peer across Eyebright's surgical treatment and equipment categories.
• STAAR Surgical: Specialist in phakic IOLs (ICL) for myopia correction, directly comparable to Eyebright's 龙晶®PR phakic posterior chamber IOL launched in 2025. STAAR is the dominant global phakic IOL player and Eyebright's most direct competitor in that specific niche.
• CooperVision: Global contact lens manufacturer (clariti, MyDay, Biofinity) competing directly with Eyebright's silicone hydrogel daily disposables, toric, and multifocal contact lens ranges in both Chinese and international markets.
• Ovctek (欧普康视): Leading Chinese orthokeratology lens manufacturer (300595.SZ) and the dominant domestic player in pediatric myopia control — Eyebright's closest direct competitor in the ortho-K and myopia control segment in China.
• HOYA Corporation: Japanese IOL manufacturer (iSert, Vivinex) and contact lens producer — competes with Eyebright in premium IOLs and specialty contact lenses globally.

Regional players

• Haohai Biological Technology (昊海生物科技): Shanghai-listed Chinese ophthalmic company (06826.HK) with overlapping portfolio in IOLs, viscoelastic solutions (OVD), and orthokeratology — a domestic Chinese peer comparable in product mix but with stronger historical presence in OVDs and aesthetic biopharmaceuticals.

Broad incumbents

• Topcon Healthcare: Broad ophthalmic diagnostics and equipment incumbent (OCT, fundus imaging, refraction systems) that overlaps with Eyebright's surgical imaging and myopia-management diagnostic ecosystem, though Topcon's portfolio is heavily weighted toward diagnostic instrumentation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eyebright